The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Brain tumours: classification and genes
Open accessAbstract
his paper aims to provide an outline of the surgical pathology of the most common tumours of the nervous system in children and adults, and briefly summarise their common genetic changes.The reader is referred to more comprehensive texts for further details about brain tumour classification and the genetic abnormalities of these tumours. 1 CLASSIFICATION cMost recent classifications of brain tumours build on the 1926 work of Bailey and Cushing. 2 This classification named tumours after the cell type in the developing embryo/fetus or adult which the tumour cells most resembled histologically.The cell of origin of the majority of brain tumours is unknown as no pre-malignant states are recognised, as is the case in some epithelial tumour forms.In some tumours, cells may be so atypical that it is difficult to compare them with any normal cell type-hence the use of terms such as glioblastoma.Many unsound or illogical terms have remained in the classifications, as once established in a complex medical setting they are difficult to change.In this paper the terminology and definitions of the World Health Organization classification of 2000 will be exclusively used. 1 There are more than 120 entities in this classification and here we will concentrate on those that most frequently occur in adults and children.These are the pilocytic astrocytomas, ependymomas, and medulloblastomas in children, and the diffuse astrocytic tumours (including astrocytoma, anaplastic astrocytomas, and glioblastomas), oligodendrogliomas, and meningiomas in adults.Tumours of the central nervous system often have a wide morphological spectrum and classification is dependent on the recognition of areas with the characteristic histology for a particular tumour type.Immunocytochemical methods may be required to demonstrate the expression by the tumour cells of an antigen typically expressed by a particular cell type and thus to assist in classification.Unfortunately there are no antibodies that unequivocally identify the different tumour types.The presence or absence of an antigen only adds a further piece of information helping to indicate the tumour type.Four malignancy grades are recognised by the WHO system, with grade I tumours the biologically least aggressive and grade IV the biologically most aggressive tumours.The histological criteria for malignancy grading are not uniform for all tumour types and thus all tumours must be classified before the malignancy grade can be determined.Only one or two malignancy grades can be attributed to some tumour types.Brain tumours are well known to progress, becoming more malignant with time.Such progression will initially be focal.A patient's diagnosis is based on the most malignant part of the tumour.Thus it is of the utmost importance to sample the tumour adequately in order to determine its type and judge its malignant potential.It follows that malignancy grading on biopsies/stereotactic biopsies is always a minimum grading as more anaplastic regions may be present in non-biopsied areas.Cytotoxic or radiation therapy before histological diagnosis may make classification and malignancy grading extremely difficult or impossible.The clinical implications of tumour classification and malignancy grading have been empirically determined.The application of objective methods of measuring cell proliferation and death in tumours to malignancy grading is conceptually attractive but have yet to be accepted and utilised in the malignancy grading of brain tumours.The MIB 1 antibody recognising the same antigen as Ki67 as well as other antibodies identifying antigens associated with proliferation (for example, Cdc6 and Mcm5) can be used efficiently on formalin fixed, paraffin embedded tissues following microwave antigen retrieval.3 4 However, wide variations in the proliferation indices are observed in different areas of individual brain tumours and this has resulted in difficulties in defining relevant proliferation levels.The same applies to the assessment of the numbers of cells undergoing apoptosis.The advances in neuroradiology and parallel improvements in stereotactic and surgical techniques permit the biopsy of just about any neoplastic or non-neoplastic lesion in the central nervous system (CNS).The list of potential diagnoses is thus vast.The neuropathologist may be expected to make a diagnosis on the basis of often very small and fragmented biopsies.He thus ii2 www.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
Tumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699
Sugawa, N., Ekstrand, A. J., James, C. D., & Collins, V. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.21.8602 · Cited by 594
Self-citationNovel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma
Gilbertson, R., Hernan, R., Pietsch, T., Pinto, L., Scotting, P., Allibone, R., Ellison, D., Perry, R., Pearson, A., & Lunec, J. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1146 · Cited by 60
Cited by
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
A Review on a Deep Learning Perspective in Brain Cancer Classification
Tandel, G. S., Biswas, M., Kakde, O. G., Tiwari, A., Suri, H. S., Turk, M., Laird, J., Asare, C., Ankrah, A. A., Khanna, N. N., et al. (2019) · Cancers · doi:10.3390/cancers11010111 · Cited by 466
Zhang, X., Gejman, R., Mahta, A., Zhong, Y., Rice, K. A., Zhou, Y., Cheunsuchon, P., Louis, D. N., & Klibanski, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3885 · Cited by 330
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
Metadata
- Authors
- Collins, V. P.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2004-06-01
- Volume
- 75
- Issue
- suppl_2
- Pages
- ii2-ii11
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2096947122
- Cited by
- 169
- References
- 6
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain tumours: classification and genes. https://app.cochat.ai/papers/10.1136/jnnp.2004.040337
- The paper
- Collins, V. P. (2004). Brain tumours: classification and genes. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.040337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.